Sanofi reports data reinforcing efficacy of RSV candidate
Sanofi’s RSV candidate for infants has demonstrated an efficacy of 79.5% against tract infections and hospitalizations, in an analysis of phase III and phase IIb data combined.
by marketwire, translated by daniel pedersen
On Wednesday, Sanofi reports a 79.5% efficacy for its respiratory syncytial virus (RSV) treatment candidate in infants with lower respiratory tract infections (LRTI), the company has announced in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer to acquire Reviral as RSV race continues
For subscribers
